Exelixis | EXEL - Cash And Equivalent


Exelixis reported $482.49M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Akebia Therapeutics USD 166.44M 29.14M Sep/2025
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Bayer EUR 5.9B 1.34B Sep/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Cytokinetics USD 225.47M 150.53M Sep/2025
Eisai JPY 301.65B 16.27B Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
Exelixis USD 482.49M 106.19M Dec/2025
Genmab DKK 1.3B 323M Jun/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
MacroGenics USD 80.13M 50.56M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Moderna USD 2.6B 1.46B Dec/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Takeda JPY 654.94B 26.55B Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Xencor USD 28.29M 16.15M Sep/2025